These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. Groseth A; Hoenen T; Alimonti JB; Zielecki F; Ebihara H; Theriault S; Ströher U; Becker S; Feldmann H J Infect Dis; 2007 Nov; 196 Suppl 2():S382-9. PubMed ID: 17940974 [TBL] [Abstract][Full Text] [Related]
49. siRNA-based approaches in cancer therapy. Devi GR Cancer Gene Ther; 2006 Sep; 13(9):819-29. PubMed ID: 16424918 [TBL] [Abstract][Full Text] [Related]
50. Advances in therapeutic bacterial antisense biotechnology. Hegarty JP; Stewart DB Appl Microbiol Biotechnol; 2018 Feb; 102(3):1055-1065. PubMed ID: 29209794 [TBL] [Abstract][Full Text] [Related]
51. Progress in the development of nucleic acid therapeutics for cancer. Kalota A; Shetzline SE; Gewirtz AM Cancer Biol Ther; 2004 Jan; 3(1):4-12. PubMed ID: 14726654 [TBL] [Abstract][Full Text] [Related]
52. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. Xu L; Anchordoquy T J Pharm Sci; 2011 Jan; 100(1):38-52. PubMed ID: 20575003 [TBL] [Abstract][Full Text] [Related]
53. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Mahato RI; Cheng K; Guntaka RV Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732 [TBL] [Abstract][Full Text] [Related]
54. Dermal/transdermal delivery of small interfering RNA and antisense oligonucleotides- advances and hurdles. Ita K Biomed Pharmacother; 2017 Mar; 87():311-320. PubMed ID: 28064104 [TBL] [Abstract][Full Text] [Related]